☆ 4.7 Editorial Material

VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

ANNALS OF ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 33, Issue 5, Pages 566-568

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.03.008

Keywords

-

Categories

Oncology

Funding

  1. AstraZeneca
  2. Merck and Co., Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.